ホーム › トリプルネガティブ乳がん › ジョージア州
ジョージア州におけるトリプルネガティブ乳がんの臨床試験
ジョージア州内の拠点で、トリプルネガティブ乳がんに関する26件の研究が参加者を募集しています。
ジョージア州内の都市
公式研究テキスト（英語）
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Emory University, Atlanta
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Winship Cancer Institute of Emory University, Atlanta
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Emory Winship Cancer Institute, Atlanta
- Augusta University, Augusta
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- City of Hope Cancer Center - Atlanta ( Site 0102), Newnan
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- University Cancer & Blood Center, LLC ( Site 0023), Athens
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06841354Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- University Cancer & Blood Center, LLC., Athens
- Piedmont Cancer Institute, Atlanta
- Northside Hospital, Atlanta
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
- Emory University (Data Collection Only), Atlanta
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05570253A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Emory University, Atlanta
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06400472Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Emory University, Atlanta
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/03更新 · NCT05846789ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
- Emory University Winship Cancer Institute, Atlanta
- Winship Cancer Institute of Emory University, Atlanta
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT06460298A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Northside Hospital, Atlanta
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Augusta University Georgia Cancer Center, Augusta
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- University Cancer & Blood Center, Athens
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/28更新 · NCT06150664A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996Study of XB010 in Subjects With Solid Tumors
- Winship Cancer Institute, Atlanta
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/22更新 · NCT06545331BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Winship Cancer Institute / Emory University, Atlanta
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/15更新 · NCT05768932Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
- Emory University Hospital, Atlanta
被験者募集中第2相
18歳以上 · 女性 · 2026/06/04更新 · NCT05741164A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Georgia Cancer Center, Augusta
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/04更新 · NCT04300556Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
- Emory University/Winship Cancer Institute, Atlanta
被験者募集中観察研究健康なボランティア歓迎
18歳以上 · 女性 · 2026/05/07更新 · NCT05877859I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Winship Cancer Institute of Emory University, Atlanta
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT01042379High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
- Emory University Hospital/Winship Cancer Institute, Atlanta
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/17更新 · NCT06492759Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
- Emory University, Winship Cancer Institute, Atlanta
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/25更新 · NCT02926690A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- Winship Cancer Institute - Emory University, Atlanta
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/30更新 · NCT06926920Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/01/26更新 · NCT06324240A Beta-only IL-2 ImmunoTherapY Study
- Emory - Winship Cancer Institute, Atlanta
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/07/09更新 · NCT05086692A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- Columbus Regional Research Institute, LLC, Columbus
被験者募集中第3相
18歳〜65歳 · 女性 · 2025/03/21更新 · NCT03671044ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。